Search results: (10000)
News DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy
Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might offer additional benefits to patients apart from effective and safe glycemic control.
News Irritable Bowel Syndrome and Non-specific Inflammatory Bowel Diseases Are Not Evolutionarily Related Diseases
The authors of the presented work attempted to compare the geographical distribution of irritable bowel syndrome and non-specific inflammatory bowel diseases and other factors related to these two diseases to reveal their potential evolutionary connection.
News Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
A recent survey among German-speaking physicians evaluated the use of non-opioid analgesics in perioperative care in children under 14 years. It focused on the use of metamizole and the monitoring of possible agranulocytosis associated with this drug.
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for chronic lymphocytic leukemia (CLL) and are now an integral part of treatment regimens, including the 1st line. Individual therapeutic approaches and strategies based on them have their advantages and disadvantages as well as their target patient group, but the concept of time-limited treatment is increasingly gaining ground. Therapy today is significantly individualized, and its optimal choice is based on the assessment of various circumstances on the patient’s part and their disease.
News EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
News ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and prevalence of HF with preserved left ventricular ejection fraction (HFpEF) rising. The following document focuses on individuals with HFpEF and supports the principles of evidence-based diagnosis and treatment of HF from 2022. It emphasizes the need for individualized care and multidisciplinary cooperation.
News How Does Artificial Intelligence Help in Drug Development?
In recent years, technologies leveraging artificial intelligence have transitioned from potentially interesting novelties to real clinical development programs. What can artificial intelligence offer the development of new drugs?
News Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to placebo on the social functioning of patients with schizophrenia. The results are comparable to other atypical antipsychotics.
News Analysis of the Benefits of Combining Enalapril/Bisoprolol in Patients with Acute MI
A recently published retrospective analysis compared the outcomes achieved by administering enalapril alone and in combination with bisoprolol in patients after acute myocardial infarction over a period of 1 year.
News Biocompatibility of 3D Printed Materials – Their Comparison, Legislation, and Practice
Printing three-dimensional (3D) objects brings new possibilities for producing personalized implants, prosthetics, and other medical devices in healthcare. One area where this technology can improve current practice is the printing of tracheostomy tubes for use in patients after laryngectomy. However, it is crucial to ensure the biocompatibility of the materials used for printing. In November 2023, a study comparing 3D printer materials in terms of their susceptibility to the growth of bacterial biofilms from Staphylococcus aureus was published in the journal 3D Printing in Medicine.
News Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice – Results from the VILP Registry
At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV). The efficacy and safety of nal-IRI + 5-FU/LV in patients with mPDAC after failure or intolerance to gemcitabine-based chemotherapy, as found in the randomized controlled study NAPOLI-1, are thus confirmed in real clinical practice in the Czech Republic.
News Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving remission or reducing disease activity by 90-100% from the baseline state (PASI 90-100) is highly probable, especially when using biological drugs from the IL-17 or IL-23 inhibitor groups. However, individually, patients may exhibit primary or secondary resistance even when using these preparations, necessitating a change in biological treatment. The following case study presents the case of a young man who achieved complete disease remission with bimekizumab after the previous failure of ixekizumab and risankizumab.
News Wireless Smart Devices Monitor Health by Detecting Sounds
The human body continuously emits various forms of acoustic-mechanical signals that can provide important information about its health. Researchers from Northwestern University in the USA have developed miniature wearable devices (wearables) capable of simultaneously detecting sounds from multiple locations on the body, thereby continuously monitoring the health of the wearer. In a pilot project, the devices were tested on prematurely born infants with breathing and intestinal motility disorders and on adults with chronic lung diseases.